Last Name

David T. Marshall

TitleChair, Department of Radiation Oncology
InstitutionMedical University of South Carolina
DepartmentRadiation Oncology
AddressP.O. Box MSC 318
169 Ashley Ave.
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Primary interests:

    Educational methods for training radiation oncology residents.

    Genitourinary and gastrointestinal cancers, prostate brachytherapy, pediatric tumors, melan oma and aggressive skin cancers, sarcomas, image-guided and stereotactic radiotherapy /radiosurgery for CNS and extracranial targets, including development of image-guided and tomotherapy approaches for GU and GI cancers.

    Worked successfully with industry leaders to achieve the first clinical application of QuickLink(TM) device to construct custom built linked seeds in the operating room for prosta te brachytherapy. Train physicians from other institutions on the use of custom built linked seeds with real-time dosimetry for prostate brachytherapy.

    Delivered first SIR-Spheres(TM) Y-90 treatment for liver metastases in the state of South Carolina.

    Delivered first Therapsheres(TM)Y-90 treatment for hepatocellular carcinoma in the state of South Carolina.

    Research Interests:

    Methods of training physicians/residents in image-based anatomy and radiotherapy planning techniques.

    Vitamin D and its influence on prostate cancer and colorectal cancer.

    Detection and implications of circulating tumor cells in prostate cancer.

    Significance of single nucleotide polymorphisms in radiation sensitivity and toxicity.

    Clinical research protocol development regarding the treatment of GU tumors, GI tumors, and pediatric malignancies.

    Integration of new technologies into patient treatment strategies including stereotactic body radiosurgery.

    Development of image-guided radiotherapy and intensity-modulated radiation therapy (IMRT) regimens including tomotherapy for the treatment of prostate cancer, cholangio-pancreatic tumors, and other malignancies of the genitourinary and gastrointestinal systems.

    Integration of small molecule therapeutic and nutritional agents with radiotherapy and chemoradiotherapy and their effects on radiosensitivity.

    DNA-radiation chemistry and molecular effects of hypoxia and other variables of the tumor microenvironment on radiotherapy. Involves detailed Monte Carlo computer simulations of radiation physics and chemistry of clinical photon beams used in radiotherapy.
    Collapse keywords
    Cancer, Cancer/Genitourinary, Cancer/Other, Drug Studies, Men-s Health, Prostate

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Kadan-Lottick N, Loh ML, Matloub YH, Marshall DT, Stork LC, Raetz EA, Wood B, Hunger SP, Carroll WL, Winick NJ. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2020 Feb 20; 38(6):602-612. PMID: 31825704.
      View in: PubMed
    2. Zhang L, Zhang J, Ye Z, Manevich Y, Townsend DM, Marshall DT, Tew KD. S-Glutathionylated Serine Proteinase Inhibitors as Biomarkers for Radiation Exposure in Prostate Cancer Patients. Sci Rep. 2019 Sep 24; 9(1):13792. PMID: 31551460.
      View in: PubMed
    3. Scott MR, Marshall DT. Public Transit and School Choice in Philadelphia: Exploring Spatial Equity and Social Exclusion. J Sch Choice. 2019; 13(2):177-197. PMID: 31186622.
      View in: PubMed
    4. Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 08 01; 24(15):3500-3509. PMID: 29661779.
      View in: PubMed
    5. Orwat KP, Beckham TH, Cooper SL, Ashenafi MS, Anderson MB, Guimaraes M, Yamada R, Marshall DT. Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver. J Gastrointest Oncol. 2017 Dec; 8(6):1072-1078. PMID: 29299369.
      View in: PubMed
    6. Anderson BJ, Wahlquist AE, Hill EG, Marshall DT, Kimchi ET, Staveley O'Carroll KF, Camp ER. The impact of metabolic syndrome on outcome and response to neoadjuvant chemoradiation in locally advanced rectal cancer patients. Int J Surg. 2016 Sep; 33 Pt A:8-12. PMID: 27432024.
      View in: PubMed
    7. Anderson BJ, Hill EG, Sweeney RE, Wahlquist AE, Marshall DT, Staveley O'Carroll KF, Cole DJ, Camp ER. The impact of surgical diversion before neoadjuvant therapy for rectal cancer. Am Surg. 2015 May; 81(5):444-9. PMID: 25975325.
      View in: PubMed
    8. Opfermann KJ, Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol. 2014 Apr; 37(2):112-6. PMID: 23211221.
      View in: PubMed
    9. Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44. PMID: 24606850.
      View in: PubMed
    10. Marshall DT, Ramey S, Golshayan AR, Keane TE, Kraft AS, Chaudhary U. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6. PMID: 24378335.
      View in: PubMed
    11. Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, Armeson KE, Marshall DT, Keane TE, Smith MT, Jones EE, Drake RR, Bielawska A, Norris JS, Liu X. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58. PMID: 24091326.
      View in: PubMed
    12. Findlay VJ, Moretz RE, Wang C, Vaena SG, Bandurraga SG, Ashenafi M, Marshall DT, Watson DK, Camp ER. Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer. Mol Carcinog. 2014 Feb; 53 Suppl 1:E130-9. PMID: 23996472.
      View in: PubMed
    13. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013 Jul; 136:233-7. PMID: 23220550.
      View in: PubMed
    14. Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol. 2013 Dec; 31(6):1339-45. PMID: 23053208.
      View in: PubMed
    15. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24. PMID: 22508710.
      View in: PubMed
    16. Taylor R, Opfermann K, Jones BD, Terwilliger LE, McDonald DG, Ashenafi MS, Garrett-Meyer E, Marshall DT. Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol. 2012 Jun; 56(3):332-7. PMID: 22697333.
      View in: PubMed
    17. Zauls AJ, Ashenafi MS, Onicescu G, Clarke HS, Marshall DT. Comparison of intraoperatively built custom linked seeds versus loose seed gun applicator technique using real-time intraoperative planning for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1010-6. PMID: 20888132.
      View in: PubMed
    18. Fuller CD, Nijkamp J, Duppen JC, Rasch CR, Thomas CR, Wang SJ, Okunieff P, Jones WE, Baseman D, Patel S, Demandante CG, Harris AM, Smith BD, Katz AW, McGann C, Harper JL, Chang DT, Smalley S, Marshall DT, Goodman KA, Papanikolaou N, Kachnic LA. Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):481-9. PMID: 20400244.
      View in: PubMed
    19. Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol. 2010 Feb; 183(2):634-9. PMID: 20018308.
      View in: PubMed
    20. Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15. PMID: 19945310.
      View in: PubMed
    21. Watkins JM, Marshall DT, Patel S, Giglio P, Herrin AE, Garrett-Mayer E, Jenrette JM. High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol. 2009 Jul; 93(3):343-8. PMID: 19142584.
      View in: PubMed
    22. Aydogan B, Bolch WE, Swarts SG, Turner JE, Marshall DT. Monte carlo simulations of site-specific radical attack to DNA bases. Radiat Res. 2008 Feb; 169(2):223-31. PMID: 18220458.
      View in: PubMed
    23. Mitas MC, Chaudhary UB, Marshall DT, Gattoni-Celli S. Detection of circulating tumor cells in the peripheral blood of patients with androgen-independent, advanced or metastatic prostate cancer. Am J Hematol. 2008 Jan; 83(1):87. PMID: 17724705.
      View in: PubMed
    24. Marshall DT. Options and recent advances in permanent brachytherapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:28-31. PMID: 18163942.
      View in: PubMed
    25. Gillespie MB, Marshall DT, Day TA, Mitchell AO, White DR, Barredo JC. Pediatric rhabdomyosarcoma of the head and neck. Curr Treat Options Oncol. 2006 Jan; 7(1):13-22. PMID: 16343365.
      View in: PubMed
    26. Bravo G, Gagnon M, Wildeman S, Marshall DT, Pâquet M, Dubois MF. Comparison of provincial and territorial legislation governing substitute consent for research. Can J Aging. 2005; 24(3):237-50. PMID: 16421848.
      View in: PubMed
    27. Marshall DT, Amdur RJ, Scarborough MT, Mendenhall NP, Virkus WW. Stage IE primary non-Hodgkin's lymphoma of bone. Clin Orthop Relat Res. 2002 Dec; (405):216-22. PMID: 12461377.
      View in: PubMed
    28. Aydogan B, Marshall DT, Swarts SG, Turner JE, Boone AJ, Richards NG, Bolch WE. Site-specific OH attack to the sugar moiety of DNA: a comparison of experimental data and computational simulation. Radiat Res. 2002 Jan; 157(1):38-44. PMID: 11754640.
      View in: PubMed
    Marshall's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description